Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
419 | 16502 | 38.2 | 79% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | STATINS | authKW | 2447902 | 19% | 43% | 3116 |
2 | EZETIMIBE | authKW | 670368 | 3% | 68% | 532 |
3 | SIMVASTATIN | authKW | 605053 | 5% | 40% | 828 |
4 | HMG COA REDUCTASE INHIBITORS | authKW | 549595 | 3% | 54% | 555 |
5 | ATORVASTATIN | authKW | 513346 | 4% | 39% | 709 |
6 | PCSK9 | authKW | 355858 | 2% | 76% | 254 |
7 | PRAVASTATIN | authKW | 292862 | 2% | 46% | 347 |
8 | HYPERCHOLESTEROLEMIA | authKW | 215972 | 4% | 18% | 657 |
9 | ROSUVASTATIN | authKW | 215204 | 2% | 41% | 282 |
10 | NIACIN | authKW | 199106 | 2% | 39% | 276 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Cardiac & Cardiovascular System | 67961 | 26% | 1% | 4262 |
2 | Peripheral Vascular Diseases | 26077 | 12% | 1% | 2019 |
3 | Pharmacology & Pharmacy | 18781 | 21% | 0% | 3547 |
4 | Medicine, General & Internal | 16053 | 16% | 0% | 2582 |
5 | Endocrinology & Metabolism | 2273 | 6% | 0% | 951 |
6 | Medicine, Research & Experimental | 1556 | 5% | 0% | 794 |
7 | Primary Health Care | 494 | 1% | 0% | 106 |
8 | Health Care Sciences & Services | 476 | 2% | 0% | 262 |
9 | Hematology | 279 | 2% | 0% | 349 |
10 | Health Policy & Services | 279 | 1% | 0% | 155 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | INTERNAL MED CLIN PHARMACOL | 32307 | 0% | 31% | 56 |
2 | CARDIOL | 31076 | 10% | 1% | 1681 |
3 | OFF HLTH PROMOT DIS PREVENT | 25329 | 0% | 57% | 24 |
4 | LIPID CLIN | 21530 | 0% | 15% | 80 |
5 | POINT MED | 21511 | 0% | 61% | 19 |
6 | BIOCHEM NEUROENDOCRINOL | 20806 | 0% | 21% | 54 |
7 | CARDIOVASC DIS PREVENT | 19527 | 0% | 15% | 69 |
8 | VASC MED ATHEROSCLEROSIS UNIT | 17636 | 0% | 34% | 28 |
9 | HEART DIS PREVENT CLIN | 16458 | 0% | 64% | 14 |
10 | VASC DIS PREVENT CLIN | 15095 | 0% | 22% | 37 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF CLINICAL LIPIDOLOGY | 64609 | 1% | 23% | 151 |
2 | ATHEROSCLEROSIS | 46420 | 3% | 5% | 520 |
3 | AMERICAN JOURNAL OF CARDIOLOGY | 40171 | 5% | 3% | 769 |
4 | CURRENT OPINION IN LIPIDOLOGY | 27898 | 1% | 11% | 142 |
5 | CURRENT ATHEROSCLEROSIS REPORTS | 18660 | 0% | 12% | 82 |
6 | ATHEROSCLEROSIS SUPPLEMENTS | 18659 | 0% | 19% | 53 |
7 | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 13672 | 0% | 13% | 56 |
8 | CURRENT MEDICAL RESEARCH AND OPINION | 13001 | 1% | 4% | 179 |
9 | CLINICAL LIPIDOLOGY | 10607 | 0% | 12% | 47 |
10 | EUROPEAN HEART JOURNAL SUPPLEMENTS | 9729 | 0% | 7% | 74 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | STATINS | 2447902 | 19% | 43% | 3116 | Search STATINS | Search STATINS |
2 | EZETIMIBE | 670368 | 3% | 68% | 532 | Search EZETIMIBE | Search EZETIMIBE |
3 | SIMVASTATIN | 605053 | 5% | 40% | 828 | Search SIMVASTATIN | Search SIMVASTATIN |
4 | HMG COA REDUCTASE INHIBITORS | 549595 | 3% | 54% | 555 | Search HMG+COA+REDUCTASE+INHIBITORS | Search HMG+COA+REDUCTASE+INHIBITORS |
5 | ATORVASTATIN | 513346 | 4% | 39% | 709 | Search ATORVASTATIN | Search ATORVASTATIN |
6 | PCSK9 | 355858 | 2% | 76% | 254 | Search PCSK9 | Search PCSK9 |
7 | PRAVASTATIN | 292862 | 2% | 46% | 347 | Search PRAVASTATIN | Search PRAVASTATIN |
8 | HYPERCHOLESTEROLEMIA | 215972 | 4% | 18% | 657 | Search HYPERCHOLESTEROLEMIA | Search HYPERCHOLESTEROLEMIA |
9 | ROSUVASTATIN | 215204 | 2% | 41% | 282 | Search ROSUVASTATIN | Search ROSUVASTATIN |
10 | NIACIN | 199106 | 2% | 39% | 276 | Search NIACIN | Search NIACIN |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | ADAMS, SP , TSANG, M , WRIGHT, JM , (2012) LIPID LOWERING EFFICACY OF ATORVASTATIN.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 12. P. - | 452 | 52% | 1 |
2 | SCHULZ, R , SCHLUTER, KD , LAUFS, U , (2015) MOLECULAR AND CELLULAR FUNCTION OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9).BASIC RESEARCH IN CARDIOLOGY. VOL. 110. ISSUE 2. P. - | 167 | 95% | 10 |
3 | STONE, NJ , ROBINSON, JG , LICHTENSTEIN, AH , MERZ, CNB , BLUM, CB , ECKEL, RH , GOLDBERG, AC , GORDON, D , LEVY, D , LLOYD-JONES, DM , ET AL (2014) 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. VOL. 63. ISSUE 25. P. 2889 -2934 | 66 | 62% | 762 |
4 | GAZZERRO, P , PROTO, MC , GANGEMI, G , MALFITANO, AM , CIAGLIA, E , PISANTI, S , SANTORO, A , LAEZZA, C , BIFULCO, M , (2012) PHARMACOLOGICAL ACTIONS OF STATINS: A CRITICAL APPRAISAL IN THE MANAGEMENT OF CANCER.PHARMACOLOGICAL REVIEWS. VOL. 64. ISSUE 1. P. 102 -146 | 242 | 48% | 106 |
5 | BERGERON, N , PHAN, BAP , DING, YC , FONG, A , KRAUSS, RM , (2015) PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITION A NEW THERAPEUTIC MECHANISM FOR REDUCING CARDIOVASCULAR DISEASE RISK.CIRCULATION. VOL. 132. ISSUE 17. P. 1648 -1666 | 119 | 89% | 26 |
6 | STONE, NJ , ROBINSON, JG , LICHTENSTEIN, AH , MERZ, CNB , BLUM, CB , ECKEL, RH , GOLDBERG, AC , GORDON, D , LEVY, D , LLOYD-JONES, DM , ET AL (2014) 2013 ACC/AHA GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL TO REDUCE ATHEROSCLEROTIC CARDIOVASCULAR RISK IN ADULTS A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES.CIRCULATION. VOL. 129. ISSUE 25. P. S1 -S45 | 64 | 60% | 708 |
7 | GOLOMB, BA , EVANS, MA , (2008) STATIN ADVERSE EFFECTS A REVIEW OF THE LITERATURE AND EVIDENCE FOR A MITOCHONDRIAL MECHANISM.AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. VOL. 8. ISSUE 6. P. 373 -418 | 262 | 45% | 188 |
8 | SEIDAH, NG , AWAN, Z , CHRETIEN, M , MBIKAY, M , (2014) PCSK9: A KEY MODULATOR OF CARDIOVASCULAR HEALTH.CIRCULATION RESEARCH. VOL. 114. ISSUE 6. P. 1022 -1036 | 105 | 80% | 92 |
9 | ALTWAIRGI, AK , (2015) STATINS ARE POTENTIAL ANTICANCEROUS AGENTS (REVIEW).ONCOLOGY REPORTS. VOL. 33. ISSUE 3. P. 1019 -1039 | 112 | 92% | 16 |
10 | AUER, J , SINZINGER, H , FRANKLIN, B , BERENT, R , (2016) MUSCLE- AND SKELETAL-RELATED SIDE-EFFECTS OF STATINS: TIP OF THE ICEBERG?.EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. VOL. 23. ISSUE 1. P. 88 -110 | 112 | 79% | 6 |
Classes with closest relation at Level 2 |